67 articles
The UNDP has issued new guidelines aimed at strengthening pharmaceutical patent examination with an emphasis on public health. The guidelines advocate for stricter standards and the use of…
The Lee and BDR decisions signal a shift in the landscape of compulsory licensing in India. This post examines the legal and policy developments leading to these outcomes,…
The Indian government’s plan to engage US trained patent examiners has sparked debate over efficiency and policy direction in the patent office. This post analyses the benefits, concerns,…
The Delhi High Court restrained Glenmark from manufacturing and marketing generic versions of Merck’s patented antidiabetic drugs. This case underscores key principles of Indian patent law and the…
This article analyses the evolution and practice of compulsory licensing in India, focusing on landmark cases and their effects on patent activity. It assesses whether compulsory licensing influences…
This article explores compulsory licensing in patents under Indian law, focusing on its impact on business strategies and public interest. Through case studies and legal analysis, the article…
The post examines the collaboration between Gilead, IPA, and Natco Pharma regarding the sofosbuvir patent in India. It analyses how voluntary licensing and innovative policies are improving access…
This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether…
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence…
This post examines the Lee Pharma v. AstraZeneca case on compulsory licensing under Indian patent law. The Controller’s decision sheds light on the standards for proving public need,…